国: スウェーデン
言語: スウェーデン語
ソース: Läkemedelsverket (Medical Products Agency)
budesonid; formoterolfumaratdihydrat
Sandoz A/S
R03AK07
budesonide; formoterol
160 mikrogram/4,5 mikrogram/inhalation,
Inhalationspulver, avdelad dos
laktosmonohydrat Hjälpämne; budesonid 160 mikrog Aktiv substans; formoterolfumaratdihydrat 4,5 mikrog Aktiv substans
Receptbelagt
Förpacknings: Inhalator, 1 x 60 doser; Inhalator, 6 x 60 doser; Inhalator, 4 x 60 doser; Inhalator, 3 x 60 doser; Inhalator, 2 x 60 doser
Avregistrerad
2018-05-07
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT {Bofunir, 160 micrograms/4.5 micrograms/inhalation, inhalation powder, pre-dispensed} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered dose (inhaled dose) contains 160 micrograms of budesonide and 4.5 micrograms of formoterol fumarate dihydrate. Each metered dose (pre-dispensed dose contained in the blister) contains 194.7 micrograms of budesonide and 6.1 micrograms of formoterol fumarate dihydrate. Excipient with known effect Lactose monohydrate: 5.4 mg per metered dose and 4.4 mg per delivered dose. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Inhalation powder, pre-dispensed. White to off-white or slightly yellow powder with no agglomerates. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ASTHMA [Nationally completed name] is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β 2 adrenoceptor agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short- acting β 2 adrenoceptor agonists. or - patients already adequately controlled on both inhaled corticosteroids and long-acting β 2 adrenoceptor agonists. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) [Nationally completed name] is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV 1 ) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy (see also section 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Route of administration: for inhalation use. Posology ASTHMA [Nationally completed name] is not intended for the initial management of asthma. The required dose of each component of [Nationally completed name] is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with com 完全なドキュメントを読む